International Journal of Retina (IJRETINA) 2019, Volume 2, Number 2.
P-ISSN. 2614-8684, E-ISSN.2614-8536
Challenges in Cytomegalovirus (Cmv) Retinitis Management
Denisa Rosati1, Sauli Ari Widjaja1,2, Ima Yustiarini1,2, Randi Montana1,3, Wimbo Sasono1,2, Muhammad
Firmansjah1,2, Ady Dwi Prakosa1,2, Moestidjab1,2, Gatut Suhendro1,2
1
Department of Ophthalmology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Academic Hospital Surabaya, Indonesia
2
Vitreoretinal Division, Department of Ophthalmology, Faculty of Medicine Universitas Airlangga,
Dr. Soetomo General Academic Hospital Surabaya, Indonesia
3
Infection Immunology Division, Department of Ophthalmology, Faculty of Medicine Universitas Airlangga,
Dr. Soetomo General Academic Hospital Surabaya, Indonesia
ABSTRACT
Introduction: HIV infection can manifest in a variety of ways in and around the eyes and it is most commonly
due to retinal microvasculopathy, neoplasm and also opportunistic infection. Those usually occur associated
with a significantly reduced CD4 T-cell counts. In this era of Highly Active Anti Retroviral Therapy (HAART)
has caused a major decreasing of the ocular involvement prevalence itself.
Case report: A 31 year-old-male came with blurred vision on the right eye, which has started 3 years ago
and slowly worsened. Central scotoma also presented previously. Patient was an HIV-AIDS, that placed him
on HAART. CD4+ T-lymphocyte count was 3 cells/mm3. The initial visual acuity was light perception and
fundus examination showed Roth spots, massive exudates and hemorrhages covering the optic disc and
decreased foveal reflex. Laboratory examination revealed positive Rubella and anti-CMV immunoglobulinG (IgG). He also suffered from lung tuberculosis and took tuberculosis medication regularly. Patient was
diagnosed with Cytomegalovirus (CMV) retinitis based on history of illness, fundus examination as well as
laboratory testing and given oral induction valganciclovir 900 mg once daily for 3 weeks followed by
maintenance dosage.
Result: After valganciclovir induction, there was significant changes with decreased peripapillary exudates,
hemorrhages and vasculitis, but the optic disc appeared pale. The patient also had bicytopenia due to
valganciclovir therapy that complicate his condition and passed away after 3 months follow up.
Conclusion: CMV retinitis is reported to occur in patient with extreme CD4 count usually less than 50
cells/mm3. The sooner of proper treatment would likely following better outcome. Making diagnosis of
immunosuppresed patient with ocular manifestations was challenging so that comprehensive eye
examination in HIV-infected individuals should be conducted. Oral valganciclovir could give satisfactory
response to decrease the progression of retinitis but risk of blindness may still occur.
Keywords: cytomegalovirus, CMV retinitis, valganciclovir, HIV-AIDS, CD4+ T-lymphocyte
Cite This Article: ROSATI, denisa. Challenges in Cytomegalovirus (CMV) Retinitis Management. International Journal of
Retina,
[S.l.],
v.
2,
n.
2,
sep.
2019.
ISSN
2614-8536.
Available
at:
https://www.ijretina.com/index.php/ijretina/article/view/91
https://doi.org/10.35479/ijretina.2019.vol002.iss002.91
INTRODUCTION
*Correspondence to:
Denisa Rosati
Department of Ophthalmology,
Faculty of Medicine Universitas
Airlangga, Dr. Soetomo General
Academic Hospital Surabaya,
Indonesia
[email protected]
Human immunodeficiency virus (HIV) remains
a major public health problem with 56,000 new
HIV infections per year in the United States.1 In
Indonesia, HIV/AIDS reported case was 3,679 in
2016.2 It is estimated that about 70 to 80% of
adult HIV/AIDS patients will experience ocular
complication during their illness.3 The majority
of ocular involvement in HIV is HIV retinopathy
and Cytomegalovirus (CMV) retinitis. HIV
retinopathy is a non-infectious microvascular
disorder characterized by cotton wool spots,
microaneurysms, retinal hemorrhages, Roth
spots and telangiectatic vascular changes.4
Published by : INAVRS https://www.inavrs.org/ | International Journal of Retina https://ijretina.com 2019; 2; 2;
80
The most common manifestation of this disorder is cotton papulo-nodular lesions found over face and neck, assessed
wool spots. Unlike infective lesion, cotton wool spot in HIV as pruritic papular eruption and molluscum contagiosum
retinopathy are transient, not visually threatening and tend (Figure 1).
to disappear within 6-12 weeks.5 Retinal hemorrhages are
seen less frequently in approximately 30% of patients with
advanced HIV/AIDS.6 It may appear as flame-shaped areas
when they affect the nerve fiber layer and as dot-and-blot
patterns when they affect the deeper layers of the retina.7 It
can be differentiated from CMV retinitis by the presence of
fewer hemorrhages and the absence of subtle iritis or
vitritis.
CMV retinitis is the most common ocular opportunistic
infection that potentially blinding of patients with HIVAIDS. This disease occurred in up to one-third of HIVinfected patients before the invention of highly active anti
retroviral therapy (HAART) and significantly associated with
CD4+ T-lymphocyte cell count <50 cells/mm3.8,9 The
incidence of CMV retinitis in the post-HAART era is
estimated to be at most 5.6 cases/100 persons/year.10 CMV
retinitis is characterized by typical white, crumbly areas of
retinal necrosis and hemorrhage which is sight threatening
if originate in posterior pole. Cotton wool spot is an early
manifestation of CMV retinitis.9 The lesions tend to enlarge
and coalesce over time, forming large, wedge-shaped areas
of involvement.11
Figure 1. Discrete papulonodular lesions (pruritic papular
eruption and moluscum contagiosum)
The visual acuity was light perception on the right eye
with mid-dilated pupil, and relative afferent pupillary defect
(RAPD) was present at presentation. There was no
inflammatory sign on anterior segment. Funduscopy
examination revealed massive soft exudates and
hemorrhages in posterior pole covering the optic disc,
Roth’s spot, necrotic lesion due to vasculitis and also
reduced foveal reflex (Figure 2). The left eye was within
normal limit. Laboratory test showed low CD4 count of 3
cells/mm3, anemia 8.5 g/dl, positive IgG rubella and antiThe clinical forms of CMV retinitis divided as typical form CMV. Chest x-ray revealed infiltrates with suspicious of lung
which appear as white spots with many hemorrhages, tuberculosis.
atypical form which appear as a zone of thinned retina and
small dot infiltrate without hemorrhages, perivascular form
or “frosted branch angiitis” and optic neuropathy which has
the worst prognosis.12 Patient with vision disturbance may
have irreversible vision loss because of direct damage to the
macula and optic nerve, retinal detachment even after CMV
retinitis has resolved and immune recovery uveitis.13 CMV
retinitis can be treated with ganciclovir or foscarnet,
administered systemically or intravitreally.14 Another drug
of choice is valganciclovir, an orally administered monovalyl
ester prodrug of ganciclovir. Induction therapy typically 900
mg once daily for 2-3 weeks followed by maintenance
therapy 450 mg once daily.10
Figure 2. Fundus photograph both eyes before oral
valganciclovir therapy. Right eye showed massive soft
CASE REPORT
exudates and hemorrhages in posterior pole
A 31-year-old man referred to the outpatient clinic with
The patient was diagnosed with cytomegalovirus (CMV)
painless visual loss on the right eye since three years ago,
retinitis
and treated with oral valganciclovir, 900 mg once
started with black dot in the center of his vision, that slowly
daily
for
3 weeks induction therapy and followed by 450 mg
worsening by time. Patient had been diagnosed with HIV
since 4 years and treated with highly active anti retroviral once daily for maintenance therapy. Funduscopy
therapy (HAART) such as Emtricitabine/Tenofovir and examination was done at the end of induction therapy,
Lopinavir/Ritonavir. This patient also suffered from lung showed significant changes with decreased peripapillary
tuberculosis and had taken anti-tuberculosis fixed-dose exudates, hemorrhages and vasculitis, but the optic disc
combinations (FDCs) for five months. Discrete painless appeared pale (Figure 3).
81
Published by: INAVRS https://www.inavrs.org/ | International Journal of Retina https://ijretina.com 2019; 2; 2;
Optical Coherence Tomography (OCT) examination showed DISCUSSION
macular thickening, intraretinal and subretinal fluid (Figure
HIV/AIDS is undoubtedly a multi systemic disease and
4).
ocular involvement occurs in up to 70% of cases during the
natural history of infection. Ocular manifestations of HIVShortly after the end of induction therapy, patient was associated spectrum are very broad and extend from a
admitted at Department of Internal Medicine ward due to simple blepharitis to blindness.12 The two most common
chronic diarrhea and bicytopenia. Hemoglobin decreased posterior segment ocular manifestations of HIV/AIDS are
to 6.5 g/dl and white blood cells (WBC) count was 1.430. He HIV retinopathy and cytomegalovirus (CMV) retinitis. In this
had to get PRC transfusion and at that time, considering his case, the patient complained of gradually painless visual
weak condition, Internal Medicine Department suggested loss with central scotoma and also massive exudates and
to postpone valganciclovir maintenance therapy since it hemorrhages on funduscopy. HIV retinopathy itself is an
appeared to be the underlying cause of his bicytopenia. occlusive microangiopathy,15 which presents as cotton wool
During hospitalized, visual acuity decreased to no light spots, microaneurysms and retinal hemorrhages.
perception.
However, cotton wool spot associated with HIV
retinopathy are usually superficial, smaller lesions that
resolve within few months.16 Patients with HIV retinopathy
rarely have immediate vision loss but there may be damage
to the retinal nerve fiber layer, decrease colour vision and
also visual field defect.17 On the other hand, CMV lesions
tend to enlarge and coalesce over time to form larger areas
of involvement. Some individuals may complain of blurred
vision, scotomas, flashlights or floaters. However,
approximately 15% of infected patients are often
asymptomatic despite the presence of extensive or vision
threatening CMV retinitis.18
Figure 3. Fundus photograph both eyes after oral
valganciclovir induction therapy. Right eye showed
CMV retinitis is the most common cause of blindness in
significant decreasing of exudates and hemorrhages
patient with HIV-AIDS. The location of infected retina,
determine the risk for vision loss. Posterior retinitis
threatens the macula and optic nerve and anterior retina
increases the risk of retinal detachment.15 In this case, the
infected retina was posteriorly, which include macula and
optic nerve. Hence, the risk of vision threatening was
greater. The patient also developed permanent and
irreversible visual impairment. Laboratory tests showed a
severe decline of CD4+ cell count to only 3 cells/μL. CD4+
cell count of less than 50 cells/μL of patient with HIV/AIDS
is a major risk factor for having active CMV retinitis
infection.(19,20) Data from the Longitudinal Study of the
Ocular Complications of AIDS (LSOCA) showed that 90%
4A
4B
patients with CMV retinitis had a recent CD4+ cell count of
<50 cells/μL and 85% was using Anti retroviral Therapy
Figure 4. Macular OCT both eyes before valganciclovir
(ART) prior to CMV diagnosis.21 Conducting routine
induction therapy (4A) and after valganciclovir induction
ophthalmology examinations especially funduscopy on
therapy (4B)
patients presenting for ART initiation with advanced disease
One week after, valganciclovir maintenance therapy was is very important.21,22
continued. During one week follow up, there was no
Before HAART, treatment of CMV retinitis was a lifelong
changes in visual acuity, funduscopy showed a pale optic
disc, necrotic lesion and decreased exudates with minimal treatment with specific anti CMV therapy that likely to
hemorrhages. Patient passed away after 3 months relapsing of retinitis after two until three weeks of
discontinuation.23
evaluation with remained ocular condition.
Published by: INAVRS https://www.inavrs.org/ | International Journal of Retina https://ijretina.com 2019; 2; 2;
82
In this HAART era, immune function that is improved by
HAART make the cessation of all anti-CMV therapy without
reactivation of CMV retinitis possible.24 Despite such
reports, anti-CMV chemotherapies are still involved
especially ganciclovir, foscarnet and cidofovir.25,30 In this
case, patient was given oral valganciclovir as induction and
maintenance therapy. It was the only drug of choice that
was available in our center. Historically, the most utilized
antiviral agent has been intravenous ganciclovir. In an
attempt to make an oral preparation with convenient
dosing that has the safety profile, efficacy and
bioavailability comparable to ganciclovir, the prodrug was
developed.26 A randomized control trial study in 2002
showed that valganciclovir, the valine ester of ganciclovir,
was found to be as effective as intravenous ganciclovir in
more convenient way. In this study, the participants were
given oral valganciclovir 900 mg twice daily as induction
therapy and the remaining received intravenous ganciclovir
5 mg/kg for three weeks.27 The main adverse effects of both
drugs were diarrhea (30%), neutropenia and anemia
(20%).28 This patient also had been admitted to internal
medicine ward due to chronic diarrhea and bicytopenia. So
that, patient on oral valganciclovir therapy must undergo
complete both ophthalmic and systemic evaluations
periodically. Depending the medication used, complete
blood count, chemistries and intraocular pressure must be
checked. Also dilated eye examinations should be
performed daily to weekly initially, then 2 weeks after
induction therapy. Patients should be undergone CD4
counts and viral load studies. As well. The other reliable
treatment for CMV retinitis is intraocular sustained release
ganciclovir implants, which have been very effective in
treating CMV retinitis but it is not readily available.29
In CMV retinitis management, it is often hard to choose
the best therapy for the patient considering the side effects.
Oral valgancyclovir has been a favourite because it doesn’t
need IV administration and hospitalization. On the other
hand, the cost of the drug is very high, longterm therapy
needs strictly good compliance and it causes some
toxicities that worsen the condition of immunosuppresed
patient. In a point that the patient get remarkable decrease
of myelosuppression, sometimes we need to postpone
therapy. Consequences, the infection might relapse or
remain. It should be avoided if hemoglobin is <8 g%,
absolute neutrophil count is less than 500 cells/L, and the
platelet count is less than 25,000/L.30 In this case, we
needed to postpone valganciclovir maintenance therapy
due to bicytopenia. Delay of therapy administration
bothered the evaluation of medication result. Patient’s
visual acuity did not improve after 3 weeks maintenance
therapy.
83
Besides, patient got sight-threatening lesions that close to
the macula and optic nerve head. The choice of therapy of
this condition is injection of 2 mg gancyclovir or 2.4 mg
foscarnet. Those medications were not available in our
center. On the follow up examination after valganciclovir
induction therapy, fundus evaluation showed a remarkable
changes. Exudates and hemorrhages were significantly
decreased and the optic disc was easier to evaluate. A pale
disc with sclerotic vascularities appeared and his visual
acuity was no light perception. As optic atrophy had already
set in the vision did not improve even though the
chorioretinitis patches had resolved.31
Visual loss adds to the overwhelming social and economic
burden not only for the patient and family itself but also
society. We support routine funduscopic examination that
has to be included in the standard WHO care package for
HIV-infected patients with advanced disease.32
CONCLUSION
Ocular involvement in HIV/AIDS infected patients is very
common with broad spectrum of manifestations including
non infectious, infectious and neoplasm. CMV retinitis with
involvement of posterior pole or owing retinal detachment
is the major factor that causes blindness. As CMV retinitis
still exists in the HAART era, we need to conduct
ophtalmological examinations as part of routine HIV care.
Furthermore, standard treatment guidelines for HIV/AIDS
patients with CD4+ cell counts < 100 cells/μL should
include ophtalmological screening.
REFERENCES
1. Lansky A, Brooks JT, DiNenno E, Heffelfinger J, et.al.
Epidemiology of HIV in the United States. JAIDS. J
Acquir Immune Defic Syndr 2010. Vol 53: 55–61: S64S68
2. Ministry of Health Republic Indonesia. HIV
Epidemiology review Indonesia. 2016-2017. P 26
3. Abu EK, Abokyi S, Yeboah DO, et.al. Retinal
Microvasculopathy is common HIV/AIDS patients : A
cross sectional study at the cape coast teaching
hospital, Ghana. Hindawi Journal of Ophtalmology
2016. Pp 1-5
4. Govender P, Hansraj R, Naidoo KS. Ocular
manifestations of HIV/AIDS : A literature review (Part
2). S Afr Optom 2011. Vol 70(2) : 81-88
5. Verma N, Kearney J. Ocular manifestations of AIDS.
Pap New Guin Med J 1996. Vol 39 196-199
6. Faia LJ, Bakri S, DooHo BK, Nader M. HIV. Emedicine
website. [Online] Available from:
http://www.emedicine. com/OPH/topic417.htm.
2007. Date accessed: 08/2008
Published by: INAVRS https://www.inavrs.org/ | International Journal of Retina https://ijretina.com 2019; 2; 2;
7. Bhatia RS. Ophthalmic manifestations of AIDS. J Ind
Acad Clin Med 2002. Vol 3 85-88
8. Sun HY, Peng XY, Li D, Mao FF, You QS, Jonas JB.
Cytomegalovirus retinitis in patients with AIDS before
and after introduction of HAART in China. Eur J
Ophthalmol 2014. Vol 24(2):209-215
9. Chen C, Guo CG, Meng L, Yu J, et.al. Comparative
analysis of cytomegalovirus retinitis and microvascular
retinopathy
in
patients
with
acquired
immunodeficiency syndrome. J Ophthalmol 2017. Vol
10 :1296-1400
10. Stewart, Michael. Optimal management of
cytomegalovirus retinitis in patients with AIDS. Clin
Ophthalmol 2010. Vol 4: 285–299
11. Cheung TW, Teich SA. Cytomegalovirus infection in
patients with HIV infection. Mount Sin J Med 1999.
Vol 66 113- 124
12. Chiotan C, Radu L, Serban R, et.al. Posterior segment
ocular manifestations of HIV/AIDS patients. J Med Life
2014. Vol 7(3):399-402
13. Heiden D, Ford N, Wilson D, et.al. Cytome- galovirus
Retinitis: The neglected disease of the AIDS pandemic.
Pub Lib Sci J 2007. Vol 4 1845-1851
14. McCannel C. Cytomegalovirus Retinitis. Retina and
Vitreous Section 12 . San Fransisco : American
Academy of Ophthalmology. 2016-2017. P.113
15. Jabs DA. Ocular manifestations of HIV infection. Trans
Am Ophthalmol Soc 1995. Vol. 93:623
16. Holland GN. AIDS and ophthalmology: The first quarter
century. Am J Ophthalmol 2008. Vol. 145(3):397-408
17. Agarwal A, Singh R, Sharma A, et.al. Ocular
manifestations
in
patients
with
human
immunodeficiency virus infection in the pre-HAART
versus the HAART era in the North Indian population.
Ocular Immunol Inflamm 2016 :396-404
18. Cheung TW, Teich SA. Cytomegalovirus infection in
patients with HIV infection. Mount Sin J Med 1999.
Vol. 66 :113- 124.
19. Ausayakhun S, Keenan JD, Ausayakhun S. Clinical
features of newly diagnosed cytomegalovirus retinitis
in northern Thailand. Am J Ophthalmol 2012. Vol.
153(5):923-931.
20. Leenasirimakul P, Liu Y, Jirawison C, et.al. Risk factors
for CMV retinitis among individuals with HIV and low
CD4 count in northern Thailand: Importance of access
to healthcare. Br J Ophthalmol 2016. Vol. 100:10171021
21. Jabs DA, van Natta ML, Holbrook JT, et.al. Longitudinal
study of the ocular complications of AIDS: 1. Ocular
diagnoses at enrollment. Ophthalmology 2007. Vol.
114(4):780- 786
22. Tun N, Smithuis FM, London N, et.al. Mortality in
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
patients with AIDS-related cytomegalovirus retinitis in
Myanmar. Clin Infect Dis 2014. Vol. 59(11):1650.
Studies of the Ocular Complications of AIDS Research
Group in collaboration with the AIDS Clinical Trials
Group. Mortality in patients with the acquired
immunodeficiency syndrome treated with either
foscarnet or ganciclovir for cytomegalovirus. N Engl J
Med 1992. Vol..326:213-220
Jabs DA, Bolton SG, Dunn JP. Discontinuing
anticytomegalovirus therapy in patients with immune
reconstitution after combination antiretroviral
therapy.Am J Ophthalmol 1998. Vol.126:817-22
Spector SA, Weingeist T, Pollard RB, et.al. A
randomized, controlled study of intravenous
ganciclovir therapy for cytomegalovirus peripheral
retinitis in patients with AIDS. J Infect Dis 1993. Vol.
69:557-63
Patil J, Sharma A, Kenney C. Valganciclovir in the
treatment of cytomegalovirus retinitis in HIV-infected
patients. Clin Ophthalmol 2010. Vol 4: 111-119
Martin DF, Sierra-Madero J, Walmsley S, et.al.
Valganciclovir Study Group. A controlled trial of
valganciclovir
as
induction
therapy
for
cytomegalovirus retinitis. N Engl J Med. 2002. Vol
346(15):1119-1126
Liu Y, Chen AS, Kamphaengkham S, et.al. Diagnostic
utility of ocular symptoms and vision for
cytomegalovirus retinitis. PLoS One 2016. Vol
11(10):e0165564
Jung D, Dorr A. Single-dose pharmacokinetics of
valganciclovir in HIV and CMVseropositive subjects. J
Clin Pharmacol 1999. Vol 39(8):800-804
Ho M, Invernizzi A, Zagora S, et al. Presenting Features,
Treatment and Clinical Outcomes of Cytomegalovirus
Retinitis: Non-HIV Patients Vs HIV Patients.
OcularImmunology and Inflammation. 2019;29:535542.
Musch DC, Martin DF, Gordon JF, et.al. Treatment of
cytomegalovirus retinitis with a sustained-release
ganciclovir implant. The Ganciclovir Implant Study
Group. N Engl J Med. 1997. Vol 337(2):83-90
Heiden D, Saranchuk P, Tun N, et al. We urge WHO to
act on cytomegalovirus retinitis. Lancet Glob Health
2014. Vol. 2(2):e76-e77
This work licensed under Creative Commons Attribution
Published by: INAVRS https://www.inavrs.org/ | International Journal of Retina https://ijretina.com 2019; 2; 2;
84